艾本与放疗联合治疗恶性肿瘤骨转移的临床疗效

目的:探讨艾本(伊班膦酸钠)全身用药与局部放疗相结合治疗恶性肿瘤局限性骨转移的临床疗效.方法:80例恶性肿瘤局限性骨转移患者随机分为两组,艾本静脉滴注加局部放疗40例(治疗组);单放组40例,只采用局部放疗(对照组).结果:治疗组疼痛缓解率为92.5%,对照组疼痛缓解率为82.5%,两组间比较无明显差异(P＞0.05);溶骨病灶再钙化的有效率治疗组为76.7%,而对照组仅为27.8%,两组比较有显著性差异(P＜0.001);治疗组出现第二部位骨转移的机率明显低于对照组(P＜0.05);1年生存率治疗组明显高于对照组(P＜0.05).两组患者不良反应的发生率相似,无显著性差异(P＞0.05).结论:艾本联合放疗治疗局限性骨转移,具有止痛快、疗效确切、高效修复溶骨病灶,并能防止新转移灶的发生及较高的生存率等优点.

Therapeutic Effect of Combination of Radiotherapy with Ibandronate in Bone Metastases

Objective: To evaluate therapeutic effect of Aiben(Ibandronate) combined with local radiotherapy in cancer patients with limited bone metastases. Methods: 80 cancer patients with limited bone metastases were divided randomly into two groups, the treated group (40 cases) received intravenously ibandronate combined with local radiotherapy while the control group (40 cases) received local radiotherapy only. Results: Response rate of bone pain relief was 92.5% in the treated group and 82.5% in the control group. There was no statistical significant difference between two groups (P>0.05). Concerning total recalcification rate, 76.7% and 27.8% respectively in two groups, the therapeutic effect in the treated group was much better than that in the control group (P<0.001). Comparing with control group, the treated group had fewer new bone metastases (P<0.05). And one-year survival rate in treated group was much higher than that in control group. There was no statistical difference in adverse events between the two groups. Conclusion: there were some advantages of a fast and substantial pain relief, a high recalcification rate of lytic lesion, a reduction of new bone metastases and a high survival rate in Aiben treated group.